**Azitra, Inc. Reports Financial Results for Fiscal Year 2025**

Azitra, Inc., a clinical-stage biopharmaceutical company focused on precision dermatology, reported a net loss of $11.0 million for the fiscal year ended December 31, 2025, compared to a net loss of $9.0 million for the previous fiscal year. The company generated no revenue in 2025, a decrease from the $7,500 in service revenue recorded in 2024 under a joint development agreement. Research and development expenses increased slightly to $4.8 million in 2025 from $4.7 million in 2024, driven by increased spending on the ATR-01 and ATR-04 programs, offset by decreased spending on the ATR-12 program and consultant expenditures. General and administrative expenses decreased slightly to $6.1 million from $6.3 million in the prior year, primarily due to decreased salaries and benefits, legal fees, and hiring costs, offset by increased spending on business consultants, public relations, and software.

The company highlighted key operational developments, including the progression of its lead programs, ATR-12 and ATR-04, into clinical trials. Azitra dosed the first patient in its Phase 1b clinical trial for ATR-12 in Netherton syndrome in August 2024 and reported initial safety results in the first half of 2025. The company also dosed the first patient in its Phase 1/2 clinical trial for ATR-04 in EGFRi-associated rash in the third quarter of 2025, following IND clearance from the FDA in August 2024 and Fast Track designation in September 2024. The company is planning to perform lead optimization and IND-enabling studies for ATR-01 in 2026. As of December 31, 2025, Azitra had 13 employees and full-time consultants.

Azitra's financial position includes total assets of $5.0 million and working capital of $2.0 million as of December 31, 2025. The company completed several public offerings and entered into an equity line of credit during 2025, generating net proceeds of approximately $9.7 million. The company's independent registered public accounting firm issued a report stating that Azitra's recurring losses and negative cash flow raise substantial doubt about its ability to continue as a going concern.

Looking ahead, Azitra anticipates that research and development expenses will increase significantly due to planned clinical trial activity and continued development of product candidates. The company intends to seek additional funding through various sources, including equity and debt offerings, federal grants, licensing fees, and joint ventures. Azitra is also evaluating strategic partnerships to maximize the potential of its precision dermatology programs and considering out-licensing opportunities for its proprietary technologies in non-core areas. The company is also committed to achieving compliance with the NYSE American continued listing standards.

About Azitra, Inc.

Azitra, Inc. is a clinical-stage biopharmaceutical company developing precision dermatology therapies using engineered proteins and live biotherapeutic products derived from a proprietary microbial library of over 1,500 bacterial strains. Focusing on genetically engineered Staphylococcus epidermidis, Azitra creates topical treatments targeting rare and chronic skin diseases, leveraging AI-driven strain screening and licensed genetic engineering technologies to deliver therapeutic proteins directly into the skin for improved disease management.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.